secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001493152-25-010282
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology relieved of $3.1M funding obligation for Phase 2 sarcoma study
--------------------------------------------------------------------------------

- Amendment No. 1 to clinical trial agreement with GEIS relieves Lixte of approx $3,095,000 obligation for randomized Phase 2 portion.
- Phase 1b recruitment completed in Q3 2024; initial toxicity and preliminary efficacy data expected Q4 2025.
- Study overall expected to be completed and report prepared by Dec 31, 2026.
- Lixte's lead compound LB-100 studied with doxorubicin for advanced soft tissue sarcomas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225010282/0001493152-25-010282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225010282/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer